Morgan Stanley Remains a Buy on Collins Foods (CLLFF)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Bales is an analyst with an average return of -2.2% and a 39.70% success rate. Bales covers the Consumer Cyclical sector, focusing on stocks such as Corporate Travel Management Limited, Flight Centre Travel Group Limited, and WEB Travel Group.
Collins Foods has an analyst consensus of Strong Buy, with a price target consensus of $6.27, a 4.50% upside from current levels. In a report released on June 25, Canaccord Genuity also upgraded the stock to a Buy with a A$9.65 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Here's when the economic data may start showing the tariff impact
The US economy will undoubtedly feel the impact of President Trump's tariffs. But when might it start showing up in the data? Morgan Stanley chief global economist Seth Carpenter took a closer look to get a rough idea. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. Related Videos US GDP Grows by 3% in Second Quarter IMF's Gourinchas Says Tariffs Causing Tepid Growth Job openings data falls short of estimates Tariff deadline, jobs report, Exxon earnings: What to Watch Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Is Wall Street Bullish or Bearish on Bristol-Myers Stock?
Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) is a leading biopharmaceutical company that discovers, develops, licenses, manufactures, markets, and sells innovative medicines across several therapeutic areas. Valued at a market cap of $93.6 billion, the company offers products for oncology, haematology, immunology, cardiovascular, and neuroscience, among others. This healthcare giant has lagged behind the broader market over the past 52 weeks. Shares of BMY have declined 6.3% over this time frame, while the broader S&P 500 Index ($SPX) has soared 17%. Moreover, on a YTD basis, the stock is down 18.7%, compared to SPX's 8.2% gain. More News from Barchart Morgan Stanley Says Nvidia Has 'Exceptional' Strength. Should You Buy NVDA Stock Here? Dear MicroStrategy Stock Fans, Mark Your Calendars for July 31 2 Growth Stocks Wall Street Predicts Will Soar 74% to 159% Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Narrowing the focus, BMY has also underperformed the SPDR S&P Pharmaceuticals ETF's (XPH) 1.8% drop over the past 52 weeks and 2.2% loss on a YTD basis. On Jul. 31, BMY released its Q2 results. The company's top line grew marginally year-over-year to $12.3 billion. Lower legacy portfolio revenue was more than offset by higher sales in the growth portfolio. Meanwhile, on the earnings front, its adjusted EPS of $1.46 declined 29.5% from the year-ago quarter, whereas its adjusted net income fell 27.1% year-over-year, reaching $3.6 billion. Looking ahead to fiscal 2025, BMY raised its revenue guidance to a range of $46.5 billion to $47.5 billion, and updated its adjusted EPS outlook to be between $6.35 and $6.65. For the current fiscal year, ending in December, analysts expect BMY's EPS to grow by a notable 446.1% year over year to $6.28. The company's earnings surprise history is promising. It topped the consensus estimates in each of the last four quarters. Among the 26 analysts covering the stock, the consensus rating is a 'Moderate Buy' which is based on seven 'Strong Buy,' 18 "Hold,' and one "Strong Sell' rating. The configuration has remained consistent over the past three months. On Jul. 29, Carter Gould from Cantor Fitzgerald maintained a 'Hold' rating on BMY with a price target of $55, indicating a 19.6% potential upside from the current levels. The mean price target of $55.48 represents a 20.7% premium from BMY's current price levels, while the Street-high price target of $68 suggests an ambitious upside potential of 47.9%. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
42 minutes ago
- Yahoo
APA Corporation Stock: Analyst Estimates & Ratings
With a market cap of $7 billion, APA Corporation (APA) is a leading independent energy company engaged in the exploration, development, and production of natural gas, crude oil, and natural gas liquids. With operations spanning the U.S., Egypt, the North Sea, and offshore Suriname, APA plays a significant role in global energy markets. Shares of the Houston, Texas-based company have underperformed the broader market over the past 52 weeks. APA stock has declined 37.2% over this time frame, while the broader S&P 500 Index ($SPX) has gained over 17%. In addition, shares of APA Corporation have dropped 15.6% on a YTD basis, compared to SPX's 8.2% rise. More News from Barchart Morgan Stanley Says Nvidia Has 'Exceptional' Strength. Should You Buy NVDA Stock Here? 2 Growth Stocks Wall Street Predicts Will Soar 74% to 159% Dear MicroStrategy Stock Fans, Mark Your Calendars for July 31 Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Looking closer, the oil and natural gas producer stock has also lagged behind the Energy Select Sector SPDR Fund's (XLE) 5.5% dip over the past 52 weeks. Shares of APA climbed 4.5% following its Q1 2025 results on May 7. The company posted adjusted EPS of $1.06 and revenue of $2.6 billion, beating analysts' estimates. The company reported adjusted production of 398,000 BOE/day and achieved significant cost efficiency, lowering full-year development capital guidance by $150 million. APA also doubled its 2025 expected run-rate savings to $225 million and announced a promising Sockeye-2 discovery well in Alaska with superior reservoir quality. For the current fiscal year, ending in December 2025, analysts expect APA's adjusted EPS to decrease 22.6% year-over-year to $2.92. The company's earnings surprise history is mixed. It beat the consensus estimates in two of the last four quarters while missing on two other occasions. Among the 26 analysts covering the stock, the consensus rating is a 'Hold.' That's based on five 'Strong Buys,' one 'Moderate Buy,' 16 'Hold' ratings, one 'Moderate Sell,' and three 'Strong Sells.' On Jul. 22, Raymond James raised its price target on APA to $26 and maintained an 'Outperform' rating, citing oil price recovery and stable management activity despite ongoing macro uncertainty. As of writing, the stock is trading below the mean price target of $22.80. The Street-high price target of $35 implies a potential upside of 79.7% from the current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
